Participate in a HD Clinical Trial or Study

Clinical Trials

Roche

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's Disease.
ENROLLING NOW: The purpose of the study is to evaluate the efficacy, safety, and biomarker effects of RG6042 compared with placebo in subjects with Huntington's disease.

Wave Life Sciences

PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of WVE-120102 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).
ENROLLING NOW: The purpose of the study is to evaluate the safety and tolerability of a single dose of WVE-120102 in subjects with early manifest Huntington's disease.

Vaccinex

A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503
ENROLLMENT CLOSED: The purpose of this study is to assess the safety and efficacy of monthly IV administration of a single dosage of VX15/2503 in Huntington's disease.

Teva

A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease
ENROLLMENT CLOSED: The purpose of this study is to assess the efficacy and safety of different doses of laquinimod in Huntington's disease.

Omeros

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Sequential, Cohort Study to Evaluate Safety and Efficacy of OMS643762 in Subjects with Huntington’s Disease
ENROLLMENT CLOSED: The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in subjects with Huntington's disease.

Teva

A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
ENROLLMENT CLOSED: The purpose of this study is to compare the efficacy and safety of different doses of pridopidine in the treatment of motor impairment in Huntington's disease.

Reach2HD

A randomized, double-blind, placebo-controlled study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington disease.
STUDY COMPLETED

Siena

Open-label Food Effect Study With SEN0014196 in Subjects With Huntington’s Disease
STUDY COMPLETED

 


Observational Trials

Enroll-HD

Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
ENROLLING NOW: A longitudinal, observational, multinational study that will integrate two existing Huntington's Disease (HD) registries, REGISTRY in Europe and COHORT in North America and Australia, while also expanding to include sites in Latin America and Asia. With no end date and annual assessments, the goal of Enroll-HD is to build a large and rich database of longitudinal clinical information and biospecimens. This database will serve as a basis for future studies aimed at developing tools and biomarkers for progression and prognosis, identifying clinically relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies.

COHORT

Cooperative Huntington’s Observational Research Trial (COHORT)
ENROLLMENT CLOSED

 


Experimental Studies

UCSD Huntington’s Disease – Behavioral Questionnaire
ENROLLING NOW: A single-center observational study designed to assess behavioral changes characteristic of HD, including apathy, depression, irritability, anxiety, disinhibition, difficulty prioritizing and initiating activities. The HD-BQ consists of 30 items with a 3-point rating scale and takes about 5 minutes to complete. The study will be conducted at UCSD.

Plasma and Salivary Biomarkers for Huntington’s Disease
ENROLLING NOW: A single-center observational study designed to assess the potential for saliva and plasma to serve as biospecimens for accessible biomarkers in Huntington’s disease. Upon visit, 4 mL of saliva and 2 tsp of blood will be collected and analyzed for huntingtin protein and various biomarkers. Such biomarkers may serve as a utility for symptom onset and, perhaps disease severity. The study will be conducted at UCSD.

Estimating Huntington’s Disease Onset Using a Low-Cost Balance Assessment
ENROLLING NOW: A single-center, observational study designed to enhance the estimate of Huntington’s disease onset using a simple and practical body sway assessment device (i.e. BTrackS™). A brief balance assessment will be administered with and without a Paced Auditory Serial Addition Test (PASAT) to subjects with HD, at-risk for HD, and non-HD control subjects. The study will be conducted at UCSD.

Handwriting Movement Abnormalities as an Early Biomarker of Transition to Manifest Huntington’s disease
ENROLLING NOW: A single-center, observational study designed to test whether handwriting movement abnormalities can distinguish individuals at risk for developing HD from normal controls. The MovAlyzeR® software is used to run a brief battery of tasks consisting of five different writing patterns: simple loops, complex loops, rapid overlay circles, Archimedes’ spiral, and the sentence “The sky is blue”. The study will be conducted at UCSD.

Reaction Time in Huntington’s Disease Using the Computer Test of Information Processing
ENROLLING NOW: A single-center, observational study designed to identify reaction time deficits that may be associated with individuals diagnosed with HD. A computerized reaction time task will be administered to subjects with diagnosed with HD, at-risk for HD, and non-HD control subjects. The study will be conducted at UCSD.

Prospective Memory Deficits in Huntington’s Disease
STUDY COMPLETED: A single-center, observational study designed to identify a fundamental, yet relatively unexamined, memory deficit that may affect the execution of various daily living skills in individuals diagnosed with HD. A paper-and-pencil prospective memory task will be administered to subjects with early manifest HD and non-HD control subjects. Eligible subjects will be between the ages of 35 and 75. Participation will require one visit. The study will be conducted at UCSD. Approximately 40 subjects will be enrolled.  

Temporal Order Memory Deficits in Huntington’s Disease
STUDY COMPLETED:  A single-center, observational study designed to identify a processing deficit that may affect the execution of various daily living skills in individuals diagnosed with HD. A computerized visuospatial temporal order memory task will be administered to subjects with early manifest HD and non-HD control subjects. Eligible subjects will be between the ages of 35 and 75. Participation will require one visit. The study will be conducted at UCSD. Approximately 40 subjects will be enrolled.

Assessment of Basal Ganglia Signaling Pathways Affected in Huntington’s Disease
STUDY COMPLETED

Clinical Trial Info
Clinical trial and study information is updated periodically. Trials listed on this page may be closed. To confirm clinical trial or study availability, contact us at
858-249-0568 or cmsnell@ucsd.edu

You can also search for a UC Health Clinical Trial or find a Clinical Trial at UC San Diego Health.